Search
Lifibrol
go.drugbank.com/drugs/DB12448InvestigationalLifibrol has been used in trials studying the basic science of Hyperlipoproteinemia and Hypercholesterolemia.
MK-5108
go.drugbank.com/drugs/DB12556InvestigationalMK-5108 has been used in trials studying the treatment of Cancer, Neoplasms, Tumors.
4SC-203
go.drugbank.com/drugs/DB12669Investigational4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia.
1-benzylimidazole
go.drugbank.com/drugs/DB04581Experimental1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.
Tulobuterol
go.drugbank.com/drugs/DB12248InvestigationalTulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Citatuzumab Bogatox
go.drugbank.com/drugs/DB06072InvestigationalVB6-845 has demonstrated effective cancer cell killing properties in pre-clinical tests.
VA-MENGOC-BC®
go.drugbank.com/drugs/DB15800ExperimentalThis vaccine may also induce moderate protection against N. gonorrhoeae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine.
Bisoxatin
go.drugbank.com/drugs/DB09219ApprovedBisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine [L926]. … It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Imetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigational[A187838] Imetelstat received FDA approval in June 2024 for use in certain patients with MDS who have transfusion-dependent anemia and are unable to use ESAs.[L50883,L50888] … Imetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase.
Azelnidipine
go.drugbank.com/drugs/DB09230InvestigationalIt has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379]. … It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.